Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Novo Nordisk A/S
Develops, manufactures, markets and distributes pharmaceutical products

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products.

It operates through the Diabetes and Obesity Care; and Biopharmaceuticals segments.

The Diabetes and Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity.

The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy.

The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsvćrd, Denmark.

Number of employees : 41 971 persons.
Sales per Businesses
20152016Delta
DKK (in Million)%DKK (in Million)%
Diabetes & Obesity Care85,59079.3%88,94979.6% +3.92%
Biopharmaceuticals22,33720.7%22,83120.4% +2.21%
Sales per Regions
20152016Delta
DKK (in Million)%DKK (in Million)%
North America56,85752.7%---
Europe20,79819.3%20,68218.5% -0.56%
International14,96613.9%14,05012.6% -6.12%
Region China9,8719.1%10,4589.4% +5.95%
Japan & Korea5,4355%---
United States--57,19451.2%-
Pacific--9,3968.4%-
Managers
NameAgeSinceTitle
Lars Fruergaard Jřrgensen, MBA511991President & Chief Executive Officer
Göran Ando682005Chairman
Maziar Mike Doustdar471992Executive Vice President-International Operations
Jesper Brandgaard, MBA541999Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen, PhD571991Chief Science Officer & Executive Vice President
Anne Marie Handrup Kverneland611981Director
Stig Strřbćk531992Director
Elizabeth Anne Hewitt612012Independent Director
Sřren Thuesen Pedersen, MBA531994Director
Jeppe Fonager Christiansen582013Vice Chairman
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 2,012,564,000 1,753,082,748 87.1% 45,667,252 2.3% 68.7%
Share B 10 537,436,000 0 0.0% 0 0.0%
Shareholders
NameEquities%
Novo Nordisk Fonden 163,814,000 8.35%
The Vanguard Group, Inc. 43,045,511 2.19%
Norges Bank Investment Management 42,958,316 2.19%
Novo Nordisk A/S 39,506,323 2.01%
Capital Research & Management Co. (World Investors) 29,398,315 1.50%
Alecta Pension Insurance Mutual 28,698,000 1.46%
Jupiter Asset Management Ltd. 22,033,268 1.12%
BlackRock Fund Advisors 19,050,659 0.97%
Flossbach von Storch AG 18,034,400 0.92%
Northern Cross LLC 16,231,146 0.83%
Holdings
NameEquities%Valuation
Novo Nordisk A/S (NOVO B) 39,506,3232.01%1,881,869,869 USD
Nnit A/S (NNIT) 6,375,00025.5%196,672,766 USD
Innate Pharma (IPH) 8,908,45615.5%116,503,897 USD
Pieris Pharmaceuticals Inc (PIRS) 0
Company contact information
Novo Nordisk A/S
Novo Allé
Bagsvćrd, Capital Region 2880

Phone : +45.44.44.88.88
Web : www.novonordisk.com
Sector Pharmaceuticals - NEC
1st jan.Capitalization (M$)
NOVO NORDISK A/S20.06%96 471
JOHNSON & JOHNSON14.36%352 651
NOVARTIS12.62%224 990
ROCHE HOLDING LTD.6.62%220 358
PFIZER10.75%214 146
MERCK AND COMPANY11.43%177 633
SANOFI9.39%126 921
BAYER11.07%108 810
BRISTOL-MYERS SQUIBB COMPANY8.37%103 906
GLAXOSMITHKLINE-5.63%97 830
ELI LILLY AND COMPANY13.30%92 384
ABBOTT LABORATORIES33.90%91 233
ASTRAZENECA10.69%84 429
ALLERGAN PLC-3.50%68 416
SHIRE-18.35%47 166
TAKEDA PHARMACEUTICAL CO LTD25.96%42 995
ASTELLAS PHARMA INC-12.73%26 207
JIANGSU HENGRUI MEDICINE CO LTD27.78%24 853
CHUGAI PHARMACEUTICAL CO LTD36.07%22 808
SAMSUNG BIOLOGICS CO LTD--.--%18 629
SHIONOGI & CO LTD6.58%17 523
Connections : Novo Nordisk A/S
Fondsmćglerselskabet Maj Invest A/S
University of Copenhagen
Harno Invest A/S
Archimedes Pharma UK Ltd.
Hofor Forsyning Komplementar A/S
Bio*One Capital Pte Ltd.
Novo Nordisk China Pharmaceuticals Co. Ltd.
EUSA Pharma (Europe) Ltd.
EUSA Pharma (UK) Ltd.
RAND Health
The International Centre for Missing & Exploited Children
Haldor Topsoe A/S
Novo Holdings A/S
Essex Woodlands Health Ventures UK Ltd.
Novo Nordisk Holding Ltd.
SWMF Life Science Venture Fund LP
Steno Diabetes Center A/S
NNE Pharmaplan A/S
Novo Nordisk Fonden
Melrose Holdings Plc
Novo Nordisk Region Japan & Korea A/S
Silverwood Property Ltd.
Novo Nordisk Region Europe A/S
HOFOR Forsyning Holding A/S
Novo Nordisk Region International Operations A/S
Hofor Forsyning A/S
Novo Nordisk Gsc Holding A/S
Fondsmćglerselskabet Maj Invest A/S (Broker)
Novo Nordisk Pharmaceuticals A/S
Maj Invest Holding A/S
Novo Nordisk Invest 2 A/S
Novo Nordisk Region China A/S
Novo Nordisk Region North America Ii A/S
SC Triton Industry SRL
© 2017 People , Fundamentals and Ownership